Reed-Sternberg Cell: Survival in a Hostile Sea
Overview
Authors
Affiliations
In contrast to the non-Hodgkin's lymphomas, little is known regarding the origin, genetics, and function of the Reed-Sternberg cell of Hodgkin's disease. Unlike other cancers, the neoplastic cell of Hodgkin's disease, the Reed-Sternberg cell, is vastly outnumbered by a surrounding intense inflammatory infiltrate. How this rare neoplastic cell originates, persists, and disseminates in a presumably hostile cellular environment has remained a mystery. Understanding the biology of the Reed-Sternberg cell has been impeded by the rarity of the cell in tumor tissue. Herein, we describe how the application of single-cell genetic analysis has revealed a clonal and, possibly, germinal center B-cell origin of the Reed-Sternberg cell. By phenotype and function, Reed-Sternberg cells are highly interactive with their cellular microenvironment through cell-cell adhesion, expression of members of the tumor necrosis factor receptor superfamily, and elaboration of cytokines. Perhaps by their mimicry of immune system cells with antigen-presenting function, Reed-Sternberg cells mediate the unusual clinical and pathologic features of Hodgkin's disease: intense tissue inflammatory infiltrate, fibrosis, and constitutional symptoms.
Pavlovic A, Miljak A, Brzica K, Glavina Durdov M Biomedicines. 2024; 12(8).
PMID: 39200145 PMC: 11352119. DOI: 10.3390/biomedicines12081680.
Al-Khatib S, Shabaneh A, Abdo N, Al-Eitan L, Al-Mistarehi A, Khader Y PLoS One. 2022; 17(7):e0272312.
PMID: 35905120 PMC: 9337659. DOI: 10.1371/journal.pone.0272312.
Hodgkin lymphoma: an update on its biology with new insights into classification.
Mani H, Jaffe E Clin Lymphoma Myeloma. 2009; 9(3):206-16.
PMID: 19525189 PMC: 2806063. DOI: 10.3816/CLM.2009.n.042.
[Receptor tyrosine kinases in Hodgkin lymphoma as possible therapeutic targets].
Renne C, Hansmann M, Brauninger A Pathologe. 2009; 30(5):393-400.
PMID: 19506874 DOI: 10.1007/s00292-009-1157-9.
Otten H, de Gast G, Vooijs W, van der Gouw A, de Boer M, Ossevoort M Cancer Immunol Immunother. 2003; 52(9):569-75.
PMID: 14627129 PMC: 11032918. DOI: 10.1007/s00262-003-0401-z.